PharmaTher Holdings Ltd. has launched Personaliz3D Peptides™, a new division focused on personalized peptide therapies using 3D printing and artificial intelligence. This initiative aims to overcome limitations in traditional peptide compounding by offering customized doses, combination formulations, and alternative delivery methods such as gummies and patches. The division plans to integrate telemedicine, physician oversight, and qualified pharmacies into a seamless ecosystem to improve patient access and treatment precision. This launch follows positive FDA advisory committee recommendations that could pave the way for regulated compounded peptides in the U.S., signaling potential growth and innovation in personalized medicine.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
Stellantis has agreed to sell its Free2move car-sharing business to Mutares, with the transaction expected to close by the end of 2026. Free2move operates free-floating car-sharing services across 14 cities in Europe and the U.S. This sale aligns wit...
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
The Hong Kong Monetary Authority (HKMA) rated its banking sector's quantum readiness at 2.3 out of 10 and set a target for full preparedness by 2030, supported by regulatory mandates and industry tools. In contrast, Bitcoin faces similar quantum comp...
Equinor ASA has completed the third tranche of its 2026 share buy-back program, purchasing 220,000 shares between July 23 and 24 at an average price of NOK 391.49 per share. This tranche runs from July 23 to October 26, 2026, and the total value of s...
